Effects of ultrasound on apoptosis induced by anti-CD20 antibody in CD20-positive B lymphoma cells

被引:10
作者
Danno, Daisuke [1 ]
Kanno, Masatoshi [1 ]
Fujimoto, Shinichi [1 ]
Feril, Loreto B., Jr. [2 ]
Kondo, Takashi [3 ]
Nakamura, Shinobu [1 ]
机构
[1] Nara Med Univ, Sch Med, Dept Gen Med, Kashihara, Nara 634, Japan
[2] Fukuoka Univ, Sch Med, Dept Anat, Fukuoka 81401, Japan
[3] Toyama Univ, Dept Radiol Sci, Grad Sch Med & Pharmaceut Sci, Toyama 930, Japan
关键词
ultrasound; rituximab; antigen-antibody reaction; immunotherapy; B-cell lymphoma;
D O I
10.1016/j.ultsonch.2007.08.004
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Aim: The present study was conducted to examine the thermal and non-thermal effects of ultrasound on apoptosis induced by anti-CD20 monoclonal antibody (rituximab). Materials and methods: SU-DHL-4 cells, a CD20-positive cell line derived from B cell lymphomas with a BCL2 gene rearrangement, were exposed to continuous 1 MHz ultrasound for therapeutic use under an air- or CO2-saturated condition to control cavitation. Early apoptosis (EA) and secondary necrosis (SN) were examined by flow cytometry. Cavitation was determined by detecting the hydroxyl radicals derived from pyrolysis of water molecules using electron paramagnetic resonance-spin trapping. To assess thermal effects, cells were treated in a temperature-controlled water bath. Results: There was a significant additive increase in EA and EA + SN observed in cells treated with rituximab combined with heat at 42 degrees C or non-thermal ultrasound at 0.5 W/cm(2) under an air-saturated condition, where heat or ultrasound induced some cell death. A significant synergistic increase in EA and EA + SN was observed in cells treated with rituximab and ultrasound at 2.5 W/cm(2) under CO2-saturated conditions, where inertial cavitations were completely suppressed. No enhancement was observed at a temperature less than 40 degrees C or ultrasound at 0.5 W/cm2 under CO2-saturated conditions. Conclusion: These results suggest that the immuno-therapeutic application of ultrasound at relatively high-intensities combined with rituximab thus produces synergistic effects under conditions where the non-thermal and non-cavitational effects are predominant. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:463 / 471
页数:9
相关论文
共 50 条
[41]   B Cell Targeting Therapy Using the Anti-CD20 Antibody in Autoimmune Diseases [J].
Tanaka, Yoshiya .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2009, 129 (06) :675-679
[42]   Immunotherapy with anti-CD20 compounds [J].
von Schilling, C .
SEMINARS IN CANCER BIOLOGY, 2003, 13 (03) :211-222
[43]   Enhanced anti-B-cell tumor effects with anti-CD20 superantibody [J].
Zhao, YF ;
Lou, DY ;
Burke, J ;
Kohler, H .
JOURNAL OF IMMUNOTHERAPY, 2002, 25 (01) :57-62
[44]   Anti-CD20 in hematologic oncology [J].
Milpied, Noel .
PRESSE MEDICALE, 2009, 38 (05) :788-798
[45]   Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity against B-Cell Lymphoma [J].
Li, Bohua ;
Zhang, Xunming ;
Shi, Shu ;
Zhao, Lei ;
Zhang, Dapeng ;
Qian, Weizhu ;
Zheng, Lei ;
Gao, Jie ;
Wang, Hao ;
Guo, Yajun .
CANCER RESEARCH, 2010, 70 (15) :6293-6302
[46]   Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis [J].
Cotchett, Kelly R. ;
Dittel, Bonnie N. ;
Obeidat, Ahmed Z. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 49
[47]   A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma [J].
Durando, Michael ;
Gopal, Ajay K. ;
Tuscano, Joseph ;
Persky, Daniel .
ONCOLOGIST, 2024, 29 (04) :278-288
[48]   Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells [J].
Tang, Xiaolong ;
Xie, Chunmei ;
Jiang, Zhenyou ;
Li, Amin ;
Cai, Shiyu ;
Hou, Changhao ;
Wang, Jian ;
Liang, Yong ;
Ma, Dong .
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 :1063-1073
[49]   Combination therapy with the type II anti-CD20 antibody obinutuzumab [J].
Klein, Christian ;
Bacac, Marina ;
Umana, Pablo ;
Fingerle-Rowson, Gunter .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (10) :1145-1162
[50]   Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation [J].
Tallantyre, E. C. ;
Whittam, D. H. ;
Jolles, S. ;
Paling, D. ;
Constantinesecu, C. ;
Robertson, N. P. ;
Jacob, A. .
JOURNAL OF NEUROLOGY, 2018, 265 (05) :1115-1122